Form 424B5 INSMED Inc

Go back to Form 424B5 INSMED Inc

UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'

February 26, 2024 4:22 PM EST

UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.

The analyst comments "We are initiating on INSM with a Buy rating and $46 PT. INSM is a commercial-stage biotech developing therapies for pulmonary... More